8-K: DaVita Q3 2025: Meets Expectations, Boosts Buyback

DaVita Inc. reported third-quarter 2025 financial results in line with expectations, maintaining full-year guidance and increasing its share repurchase authorization.

Summary

• Consolidated revenues reached $3.420 billion for the quarter ended September 30, 2025.
• Operating income was $506 million, with adjusted operating income at $517 million.
• Diluted earnings per share (EPS) was $2.04, and adjusted diluted EPS was $2.51.
• Operating cash flow for the quarter was $842 million, and free cash flow was $604 million.
• The company refinanced its existing Term Loan B-1 with a new $1.9 billion Term Loan B-2, which included an incremental borrowing of $250 million.
• DaVita repurchased 3.3 million shares of common stock for $465 million at an average price of $140.67 per share during the quarter.
• The Board increased the authorization under the existing share repurchase program by an additional $2.0 billion, effective August 21, 2025.
• Total U.S. dialysis treatments for Q3 2025 were 7,242,725, averaging 91,680 treatments per day, representing a (0.5)% per day decrease compared to Q2 2025.
• Normalized non-acquired treatment growth in Q3 2025 compared to Q3 2024 was (0.6)%.
• Incurred $11.7 million in general and administrative charges during Q3 2025 related to a cybersecurity incident experienced in Q2 2025, with total costs of $25.2 million for the nine months ended September 30, 2025.
• Recorded equity investment losses related to Mozarc Medical Holding LLC of $51.3 million, including $25.9 million in impairment and restructuring charges, during the third quarter of 2025.
• As of September 30, 2025, DaVita provided dialysis services to approximately 293,200 patients at 3,247 outpatient dialysis centers globally.
• Integrated kidney care (IKC) patients in risk-based arrangements totaled approximately 64,900, representing an estimated $5.5 billion in annualized medical spend.

Sentiment

Score: 7

Explanation: The company met expectations and reaffirmed/slightly raised guidance, indicating stable performance despite some headwinds like negative treatment growth and one-off costs (cybersecurity, Mozarc loss). Strong cash flow and share repurchase authorization are positive, but declining net income and operating income year-over-year, along with ongoing risks, temper enthusiasm.

Positives

• Performance for the third quarter was in line with expectations, keeping the company on track to achieve full-year guidance.
• Consolidated revenues increased to $3.420 billion for Q3 2025, up from $3.263 billion in Q3 2024.
• Operating cash flow increased to $842 million for Q3 2025, compared to $810 million in Q3 2024.
• Free cash flow increased to $604 million for Q3 2025, up from $555 million in Q3 2024.
• Successfully refinanced existing Term Loan B-1 with a new $1.9 billion Term Loan B-2, demonstrating access to capital markets.
• The Board increased the share repurchase authorization by $2.0 billion, signaling confidence in the company's valuation and commitment to shareholder returns.
• Revenue per treatment increased to $410.59 in Q3 2025 from $404.58 in Q2 2025, driven by higher average reimbursement rates and increased volume of phosphate binders.
• Integrated kidney care (IKC) patients in risk-based arrangements grew to approximately 64,900, representing $5.5 billion in annualized medical spend, indicating progress in value-based care initiatives.
• The low end of the 2025 adjusted operating income guidance was slightly raised to $2,035 million (from $2,010 million).
• The low end of the 2025 adjusted diluted net income per share guidance was slightly raised to $10.35 (from $10.20).

Negatives

• Diluted earnings per share decreased to $2.04 in Q3 2025 from $2.50 in Q3 2024.
• Net income attributable to DaVita Inc. decreased to $150 million in Q3 2025 from $215 million in Q3 2024.
• Operating income decreased to $506 million in Q3 2025 from $535 million in Q3 2024.
• U.S. dialysis treatments per day decreased by (0.5)% compared to the second quarter of 2025.
• Normalized non-acquired treatment growth was negative (0.6)% compared to the third quarter of 2024.
• Incurred $11.7 million in Q3 2025 for cybersecurity incident-related general and administrative charges, with total costs of $25.2 million for the nine months ended September 30, 2025.
• Incurred $51.3 million in equity investment losses related to Mozarc Medical Holding LLC, including $25.9 million in impairment and restructuring charges.
• Debt expense increased to $150.5 million in Q3 2025 from $134.6 million in Q3 2024.
• Other loss, net increased to $41.3 million in Q3 2025 from $16.8 million in Q3 2024.
• Cash, cash equivalents, and restricted cash decreased to $795.4 million at September 30, 2025, from $1,158.6 million at September 30, 2024.

Risks

• External conditions, including general economic, marketplace, and global health conditions, and political or governmental volatility.
• The impact of the domestic political environment and related developments on the current healthcare marketplace, patients, and business.
• The continuing impact of infectious diseases on financial condition and the chronic kidney disease (CKD) population.
• Supply chain challenges and disruptions, including with respect to certain key services, critical clinical supplies, and equipment.
• The potential impact on patients and the industry from new or potential entrants in the dialysis and pre-dialysis marketplace and innovative technologies, drugs, or other treatments.
• Elevated teammate turnover or labor costs.
• The impact of continued increased competition from dialysis providers and others.
• The concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates.
• A reduction in the number or percentage of patients under commercial plans due to healthcare, immigration, or other policies, or payors implementing restrictive plan designs.
• Risks arising from potential changes in or new laws, regulations, or requirements, including the federal government shutdown and the One Big Beautiful Bill Act (OBBBA).
• Ability to successfully implement strategies with respect to Integrated Kidney Care (IKC) and Value-Based Care (VBC) initiatives and home-based dialysis.
• A reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid, or other government-based programs.
• Reliance on significant suppliers, service providers, and other third-party vendors.
• Noncompliance with privacy or security laws or any security breach, such as the cybersecurity incident experienced in 2025.
• Legal and compliance risks, such as compliance with complex and evolving government regulations.
• Ability to attract, retain, and motivate teammates, including key leadership personnel, and manage potential disruptions to business and operations.
• Changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to oral phosphate binders.
• Ability to develop and maintain relationships with physicians and hospitals, and the emergence of new models of care.
• Ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures, or other strategic transactions.
• Ability to continue to successfully expand operations and services in markets outside the United States, or to businesses or products outside of dialysis services.
• The variability of cash flows, including any extended billing or collections cycles due to defects or operational issues in billing systems or the cybersecurity incident.
• The risk of not being able to generate or access sufficient cash in the future to service indebtedness or to fund other liquidity needs.
• The effects on the company or others of natural or other disasters, public health crises, or severe adverse weather events.
• Factors that may impact the ability to repurchase stock under the share repurchase program and the timing of any such stock repurchases.
• Goals and disclosures related to environmental, social, and governance (ESG) matters, including evolving regulatory requirements.

Future Outlook

DaVita reaffirmed its full-year 2025 guidance for free cash flow at $1.0 billion to $1.25 billion. The company slightly raised the low end of its adjusted operating income guidance to a range of $2.035 billion to $2.135 billion and adjusted diluted net income per share guidance to a range of $10.35 to $11.15. Management expects to remain on track to achieve these targets, emphasizing continued investment in patient care and support for teammates and physician partners.

Management Comments

• "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance." Javier Rodriguez, CEO of DaVita.
• "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Javier Rodriguez, CEO of DaVita.

Industry Context

The dialysis industry continues to face challenges such as evolving reimbursement rates, increasing competition, and the need for innovative technologies and treatments. DaVita's focus on Integrated Kidney Care (IKC) and Value-Based Care (VBC) initiatives aligns with broader healthcare trends towards more holistic and preventative patient management, aiming to improve outcomes and manage costs. The negative non-acquired treatment growth suggests ongoing pressures on patient volumes, potentially from increased home dialysis options or other care modalities. The cybersecurity incident highlights the increasing operational risks faced by healthcare providers in a digitally connected environment.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from increased share repurchase authorization and consistent performance in line with expectations. Potential negative impact from decreased diluted EPS and net income year-over-year.
• Patients: Continued focus on providing outstanding care and investment in improving patient lives.
• Employees (Teammates): Continued support for dedicated teammates. Potential impact from elevated teammate turnover or labor costs mentioned as a risk.
• Physician Partners: Continued support for physician partners.
• Creditors: Debt refinancing indicates active debt management, with a leverage ratio of 3.37x within permitted limits.

Next Steps

• Hold a conference call on October 29, 2025, at 5:00 p.m. Eastern Time to discuss Q3 2025 results.
• Continue efforts to achieve full-year 2025 guidance for adjusted operating income, adjusted diluted net income per share, and free cash flow.
• Continue investing in improving the lives of patients and supporting teammates and physician partners.
• Potentially continue share repurchases under the increased $2.0 billion authorization.

Key Dates

Recommendation

While DaVita met its Q3 expectations and reaffirmed/slightly raised its full-year guidance, indicating operational stability, the year-over-year decline in net income and diluted EPS, coupled with negative non-acquired treatment growth, suggests underlying challenges. The significant costs from the cybersecurity incident and Mozarc investment losses are notable. The increased share repurchase authorization is a positive signal for shareholder returns. However, the mixed financial performance and ongoing industry risks, including competition and regulatory pressures, warrant a 'hold' recommendation. Investors should monitor future treatment volume trends and the impact of IKC initiatives.

Keywords

Dialysis, Kidney Care, Healthcare Services, Financial Results, Q3 2025, Earnings, DaVita, DVA, SEC Filing, 8-K, Integrated Kidney Care, Share Repurchase, Debt Refinancing, Cybersecurity Incident, Mozarc Medical